Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Laugel

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
European Journal of Immunology|April 13, 2007
Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant regionLinda Wooldridge, Anna Lissina, Jonathan Vernazza, et al.
The Journal of Biological Chemistry|March 27, 2002
Novel CD8+ T cell antagonists based on beta 2-microglobulinMeir Glick, David A Price, Anne-Lise Vuidepot, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 2, 2010
MHC class I molecules with Superenhanced CD8 binding properties bypass the requirement for cognate TCR recognition and nonspecifically activate CTLsLinda Wooldridge, Mathew Clement, Anna Lissina, et al.
Molecular Cancer Therapeutics|July 11, 2007
The HLA A*0201-restricted hTERT(540-548) peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptorMarco A Purbhoo, Yi Li, Deborah H Sutton, et al.
The Journal of Biological Chemistry|December 2, 2016
Structural Mechanism Underpinning Cross-reactivity of a CD8+ T-cell Clone That Recognizes a Peptide Derived from Human Telomerase Reverse TranscriptaseDavid K Cole, Hugo A van den Berg, Angharad Lloyd, et al.
Nature Medicine|November 11, 2008
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptorAngel Varela-Rohena, Peter E Molloy, Steven M Dunn, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 24, 2023
Enhancing Efficacy of TCR-engineered CD4 + T Cells Via Coexpression of CD8αVictoria E Anderson, Sara S Brilha, Anika M Weber, et al.
Journal for Immunotherapy of Cancer|May 16, 2022
Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?Sonia Guedan, Maik Luu, Delphine Ammar, et al.
The Journal of Clinical Investigation|March 13, 2018
Peptide mimic for influenza vaccination using nonnatural combinatorial chemistryJohn J Miles, Mai Ping Tan, Garry Dolton, et al.
Journal for Immunotherapy of Cancer|May 16, 2022
Time to evolve: predicting engineered T cell-associated toxicity with next-generation modelsEmmanuel Donnadieu, Maik Luu, Miriam Alb, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
European Journal of Immunology|April 13, 2007
Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant regionLinda Wooldridge, Anna Lissina, Jonathan Vernazza, et al.
The Journal of Biological Chemistry|March 27, 2002
Novel CD8+ T cell antagonists based on beta 2-microglobulinMeir Glick, David A Price, Anne-Lise Vuidepot, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 2, 2010
MHC class I molecules with Superenhanced CD8 binding properties bypass the requirement for cognate TCR recognition and nonspecifically activate CTLsLinda Wooldridge, Mathew Clement, Anna Lissina, et al.
Molecular Cancer Therapeutics|July 11, 2007
The HLA A*0201-restricted hTERT(540-548) peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptorMarco A Purbhoo, Yi Li, Deborah H Sutton, et al.
The Journal of Biological Chemistry|December 2, 2016
Structural Mechanism Underpinning Cross-reactivity of a CD8+ T-cell Clone That Recognizes a Peptide Derived from Human Telomerase Reverse TranscriptaseDavid K Cole, Hugo A van den Berg, Angharad Lloyd, et al.
Nature Medicine|November 11, 2008
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptorAngel Varela-Rohena, Peter E Molloy, Steven M Dunn, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 24, 2023
Enhancing Efficacy of TCR-engineered CD4 + T Cells Via Coexpression of CD8αVictoria E Anderson, Sara S Brilha, Anika M Weber, et al.
Journal for Immunotherapy of Cancer|May 16, 2022
Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?Sonia Guedan, Maik Luu, Delphine Ammar, et al.
The Journal of Clinical Investigation|March 13, 2018
Peptide mimic for influenza vaccination using nonnatural combinatorial chemistryJohn J Miles, Mai Ping Tan, Garry Dolton, et al.
Journal for Immunotherapy of Cancer|May 16, 2022
Time to evolve: predicting engineered T cell-associated toxicity with next-generation modelsEmmanuel Donnadieu, Maik Luu, Miriam Alb, et al.
Pageof 3